Feb 03, 2009 12:00am EST Pieris reports development progress for Anticalin® PRS-050, a next generation VEGF antagonist
Jul 16, 2008 12:00am EDT Wacker validates scalability of Anticalin® production with E.coli secretion technology and will produce Pieris first clinical candidate PRS-050
Nov 08, 2007 12:00am EST Pieris strengthens its management, as it prepares for the clinical development of PRS-050, an Anticalin®-based novel cancer therapy
Oct 30, 2007 12:00am EDT Pieris and Pepscan to identify GPCR-specific Anticalins® using CLIPS™ protein mimicry technology
Jul 10, 2007 12:00am EDT Pieris progresses proprietary asthma program: validation of pulmonary delivery of Anticalin®-based protein product candidate
Jun 21, 2007 12:00am EDT Pieris progresses development of its proprietary biotherapeutics platform: successful demonstration of dual targeting with Duocalin® technology
Mar 29, 2007 12:00am EDT Pieris Demonstrates Potent Anti-Tumor Activity of a VEGF-Specific Anticalin® in Preclinical Studies
